The purpose of this extension trial was to further evaluate the safety and tolerability of
oral cladribine in subjects who have previously completed treatment within Trial 25643
(CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week
treatment.
Phase:
Phase 3
Details
Lead Sponsor:
EMD Serono EMD Serono Research & Development Institute, Inc.